Cargando…

Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults

This first-in-human study (NCT03032588), conducted in Belgium, evaluated a new inactivated poliovirus vaccines (IPV) candidate based on Sabin poliovirus strains grown on the high-yield PER.C6® cell line. Healthy adults (N = 32) were randomized (1:1) to receive a single dose of PER.C6-based Sabin-IPV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leroux-Roels, Isabel, Leroux-Roels, Geert, Shukarev, Georgi, Schuitemaker, Hanneke, Cahill, Conor, de Rooij, Richard, Struijs, Martin, van Zeeburg, Hester, Jacquet, Jeanne-Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078678/ https://www.ncbi.nlm.nih.gov/pubmed/33175637 http://dx.doi.org/10.1080/21645515.2020.1812315

Ejemplares similares

Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age
por: Ong-Lim, Anna Lisa, et al.
Publicado: (2022)

An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model
por: Bockstal, Viki, et al.
Publicado: (2018)

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials
por: De Coster, Ilse, et al.
Publicado: (2021)

Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2023)

Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies
por: Resik, Sonia, et al.
Publicado: (2015)

HCV Animal Models: A Journey of More than 30 Years
por: Meuleman, Philip, et al.
Publicado: (2009)

Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2008)

The role of cell-mediated immunity against influenza and its implications for vaccine evaluation
por: Janssens, Yorick, et al.
Publicado: (2022)

Detection of H1 Swine Influenza A Virus Antibodies in Human Serum Samples by Age Group
por: Vandoorn, Elien, et al.
Publicado: (2020)

Human Immunity and Susceptibility to Influenza A(H3) Viruses of Avian, Equine, and Swine Origin
por: Vandoorn, Elien, et al.
Publicado: (2023)

The Sabin live poliovirus vaccination trials in the USSR, 1959.
por: Horstmann, D. M.
Publicado: (1991)

Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine
por: Shin, Woo-Jin, et al.
Publicado: (2018)

Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: A double-blind randomized trial
por: Leroux-Roels, Geert, et al.
Publicado: (2013)

Cell cycle and apoptosis in PER.C6(® )cultures
por: Mercier, Sarah M, et al.
Publicado: (2013)

Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant
por: Waerlop, Gwenn, et al.
Publicado: (2023)

In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine
por: Abd-Elghaffar, Asmaa A., et al.
Publicado: (2020)

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

H5N1 Influenza Vaccine Formulated with AS03(A) Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
por: Moris, Philippe, et al.
Publicado: (2010)

Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China
por: Hu, Yuemei, et al.
Publicado: (2019)

LB13. Trivalent Hepatitis B (HepB) Vaccine Yields Superior Seroprotection Rates in Adults: Results from the Phase 3 Double-Blind, Randomized Study Comparing Immunogenicity and Safety of a 3-Dose Regimen of Sci-B-Vac™ and Engerix B® (PROTECT)
por: Vesikari, Timo, et al.
Publicado: (2019)

A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2020)

Pressure for Pattern-Specific Intertypic Recombination between Sabin Polioviruses: Evolutionary Implications
por: Korotkova, Ekaterina, et al.
Publicado: (2017)

PerC Manipulates Metabolism and Surface Antigens in Enteropathogenic Escherichia coli
por: Mellies, Jay L., et al.
Publicado: (2017)

Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial
por: Wang, Yamin, et al.
Publicado: (2021)

Percs of the Job
Publicado: (1994)

Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial
por: Aldrich, Cassandra, et al.
Publicado: (2021)

Nearly Complete Genome Sequences of Type 2 Sabin-Like Polioviruses from Northern Nigerian Poliovirus Surveillance, 2016 to 2018
por: Zhao, Kun, et al.
Publicado: (2022)

Hematopoietic Cancer Cell Lines Can Support Replication of Sabin Poliovirus Type 1
por: Oosterhoff, Dinja, et al.
Publicado: (2015)

Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV)
por: Li, Zhuofan, et al.
Publicado: (2018)

Correlation between recombination junctions and RNA secondary structure elements in poliovirus Sabin strains
por: Dedepsidis, Evaggelos, et al.
Publicado: (2010)

1531. A CMV Vaccine Based on Non-Replicating Lymphocytic Choriomeningitis Virus Vectors Expressing gB and pp65 Is Safe and Immunogenic in Healthy Volunteers, Allowing for Development of a Phase II Clinical Trial in Living Donor Kidney Transplant Recipients
por: Kotton, Camille Nelson, et al.
Publicado: (2018)

Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region
por: Poovorawan, Y, et al.
Publicado: (2011)

Testing a compact mobile air purification unit, does it do the job
por: De Waegemaeker, P, et al.
Publicado: (2015)

A Sabin 1 poliovirus-based vaccine vector transfects Vero cells with high efficiency
por: Li, Changgui, et al.
Publicado: (2007)

Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children
por: Wahid, Rahnuma, et al.
Publicado: (2022)

Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults
por: Lazarus, Rajeka, et al.
Publicado: (2016)

Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial
por: Leroux-Roels, Geert, et al.
Publicado: (2018)

Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers
por: Poovorawan, Yong, et al.
Publicado: (2012)

Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine
por: Van Damme, Pierre, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gfiohv1ddv52ujvmj11u5i6274